[go: up one dir, main page]

CY1108570T1 - Gd3-μιμητικα πεπτιδια - Google Patents

Gd3-μιμητικα πεπτιδια

Info

Publication number
CY1108570T1
CY1108570T1 CY20071100467T CY071100467T CY1108570T1 CY 1108570 T1 CY1108570 T1 CY 1108570T1 CY 20071100467 T CY20071100467 T CY 20071100467T CY 071100467 T CY071100467 T CY 071100467T CY 1108570 T1 CY1108570 T1 CY 1108570T1
Authority
CY
Cyprus
Prior art keywords
amino acid
mimal
patterns
acid sequence
deleting
Prior art date
Application number
CY20071100467T
Other languages
English (en)
Inventor
Dai Ishikawa
Koichi Ogino
Takao Taki
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of CY1108570T1 publication Critical patent/CY1108570T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

GD3-μιμητικά πεπτίδια τα οποία περιέχουν αλληλουχία αμινοξέος που αντιπροσωπεύεται από οποιαδήποτε των SEQ ID NOS:1 έως 4 ή αλληλουχία αμινοξέος που λαμβάνεται από αυτές με υποκατάσταση, απαλοιφή, προσθήκη ή εισαγωγή ενός ή περισσότερων υπολειμάτων αμινοξέος και είναι ικανά σύνδεσης ειδικά προς αντι-GD3 αντίσωμα και ιατρικές συνθέσεις που περιέχουν αυτά.
CY20071100467T 2000-04-25 2007-04-04 Gd3-μιμητικα πεπτιδια CY1108570T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000124259 2000-04-25
EP01921990A EP1279677B1 (en) 2000-04-25 2001-04-23 Gd3-mimetic peptides

Publications (1)

Publication Number Publication Date
CY1108570T1 true CY1108570T1 (el) 2014-04-09

Family

ID=18634414

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100467T CY1108570T1 (el) 2000-04-25 2007-04-04 Gd3-μιμητικα πεπτιδια

Country Status (10)

Country Link
US (2) US7341994B2 (el)
EP (2) EP1616875A1 (el)
AT (1) ATE356140T1 (el)
AU (1) AU2001248822A1 (el)
CY (1) CY1108570T1 (el)
DE (1) DE60127113T2 (el)
DK (1) DK1279677T3 (el)
ES (1) ES2283399T3 (el)
PT (1) PT1279677E (el)
WO (1) WO2001081371A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998237B1 (en) * 2002-07-11 2006-02-14 Health Research, Inc. GD3 peptide mimics
US7691816B2 (en) * 2005-07-12 2010-04-06 Renovo Ltd. Pharmaceutical compositions
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604938D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
WO2011022103A2 (en) * 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. Ganglioside epitopes for treating guillain-barre syndrome
US20120258519A1 (en) * 2011-04-10 2012-10-11 Therapeutic Proteins Inc. Protein Harvesting
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
MX395154B (es) 2015-10-22 2025-03-25 Juno Therapeutics Gmbh Métodos, kits, agentes y aparatos para transducción.
SG11201909931PA (en) 2017-04-27 2019-11-28 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
EP0680338B1 (en) 1993-01-22 2003-04-16 Sloan-Kettering Institute For Cancer Research Ganglioside-klh conjugate vaccines with qs-21
CU22420A1 (es) 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
JPH10237099A (ja) 1997-02-26 1998-09-08 Immuno Japan:Kk 糖脂質糖鎖レプリカペプチド
JPH10237098A (ja) 1997-02-26 1998-09-08 Immuno Japan:Kk 糖脂質糖鎖レプリカペプチド
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof

Also Published As

Publication number Publication date
AU2001248822A1 (en) 2001-11-07
US7341994B2 (en) 2008-03-11
EP1279677B1 (en) 2007-03-07
DK1279677T3 (da) 2007-05-07
ES2283399T3 (es) 2007-11-01
US8017584B2 (en) 2011-09-13
DE60127113D1 (de) 2007-04-19
US20080125374A1 (en) 2008-05-29
PT1279677E (pt) 2007-06-12
WO2001081371A1 (en) 2001-11-01
EP1279677A4 (en) 2004-06-09
US20060058226A1 (en) 2006-03-16
EP1279677A1 (en) 2003-01-29
DE60127113T2 (de) 2007-06-14
ATE356140T1 (de) 2007-03-15
EP1616875A1 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
CY1106708T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
CY1105173T1 (el) Πρωτεϊνες συντηξης ιντepφepονης -βητα και χρησεις
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
ATE382055T1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1109699T1 (el) Νουκλεινικα οξεα που κωδικοποιουν πολυπεπτιδια πολυεπιτοπων
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE495247T1 (de) Chromoprotein und fluoroproteine
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
DE60118935D1 (de) Dna & protein bindende miniatur proteine
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
ATE393224T1 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
CY1107371T1 (el) Αυξηση της θυμοσινης στην γενετικη ανοσοποιηση
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
DK1196440T3 (da) Terapeutiske peptider afledt af subsekvenser af BPI